<DOC>
	<DOC>NCT02231658</DOC>
	<brief_summary>The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.</brief_summary>
	<brief_title>Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities. Trialrelated activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. Male or female aged 1865 years (both inclusive) T2DM diagnosis Contraindications (including known or suspected hypersensitivity) to GLP1 mimetics Use of GLP1 mimetics or DPPIV inhibitors Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>